mRNA Vaccines and RNAi Therapeutics Market Synopsis

mRNA Vaccines and RNAi Therapeutics Market Size Was Valued at USD 1.2 Billion in 2023, and is Projected to Reach USD 15.1 Billion by 2032, Growing at a CAGR of 32.1% From 2024-2032.

Vaccines and RNAi Therapeutics market can be best categorized and defined as unique technologies in the practice of medicine that are revolutionalizing absolutely the therapeutic control and prevention of diseases. Educationally, these are vaccines that use mRNA to deliver genetic instructions into a body, within a context of teaching cells to produce certain proteins or antigens that will trigger the appropriate immune response. In fact this method has demonstrated unbelievable efficiency particularly with disease causing pathogens. However, RNAi therapeutics are small interfering RNA (siRNA) that function to locate and degrade disease causing genes to synthesize proteins responsible for diseases such as cancer and hereditary diseases. Altogether, these are: Expanding the frontiers of modern Medicine through improvement in better vaccines for various life threatening diseases and treatments.

• Hence this market is expected to grow at very high rates as more applications of mRNA are discovered and RNAi therapies attracts more investors by promising to treat as many diseases as there are and it does this by selectively switching off disease related genes. There are also other corporate titans in pharma, new and traditional entrants and biotech companies that have also been making tremendous strides in this technology.
• This market cultivates big funding in research and development, Innovation as well as in the technological advancement and high competition through differentiation in product and through strategic venting. Regulators are also experiencing less challenge in granting their approval, primarily because the management of diseases requires fast actions by most countries. The establishment of innovation in health technology, improved health care spending, sound policies the growth of biotechnology, other world regions especially Asia/Pacific countries are gradually improving in terms of innovation and market size to match those of North America and Europe.

mRNA Vaccines and RNAi Therapeutics Market Trend Analysis

Rising Investment in Personalized Medicine

• One of the major trends distinguishing the mRNA Vaccines and RNAi Therapeutics market is the strategic focus on increasing personalization. Off-the-shelf- and precision diagnostics and therapeutics making use of $mRNA$ and RNA interference ($RNAi$) technologies are on the way to become the future medicine because such an experimental approach allows for the flexibility necessary for comprehensively molecular disease targeting. An increasing number of cancer cases and other genetic diseases mean that the demand for targeted treatments is high, and so biopharma organizations are interested in ways to make RNA therapies more individualized. Thus, through integrating genomic informations with mRNA and RNAi platforms, many companies expect to bring in more effective treatments with improved side effect profiles. This trend is also expected to shift the treatment model and present opportunities for key participants and newcomers to the market.

Expansion into New Therapeutic Areas

• One of the major opportunities existing in the market is the development of mRNA Vaccines and RNAi Therapeutics in new therapeutic areas other than infectious disease treatment. Although the COVID-19 situation has helped to bring mRNA technology into the mainstream application, nobody has ever dreamed that mRNA can be applied to cancer treatment, rare diseases, chronic diseases such as cardiovascular diseases. Mainly, significantly more money is being dedicated to biopharmaceuticals, mRNA treatment for cancer immunotherapy here mRNA vaccines are used to educate the immune system to identify and destroy cancer cells. Likewise, RNAi therapies are slowly finding soil in the treatment of genetic diseases like Huntington’s disease and amyloidosis. The opportunity for these technologies to combat complex diseases underlines the potential for market growth, and there are many ongoing studies that could establish future new product releases and approvals.

mRNA Vaccines and RNAi Therapeutics Market Segment Analysis:

mRNA Vaccines and RNAi Therapeutics Market Segmented on the basis of Disease Type, Route of Administration and end user.

By Disease Type, Hereditary transthyretin-mediated amyloidosis genetic segment is expected to dominate the market during the forecast period

• The mRNA Vaccines and RNAi Therapeutics market is expected to be driven by hereditary transthyretin-mediated amyloidosis (hATTR) based on disease type during the forecast period. This very rare hereditary disease arises from the inheritance of mutations in the gene that codes for transthyretin (TTR), where amyloid proteins gather in the organs and tissues, resulting in illnesses affecting the nerves, heart and the general functioning of the organs. The rational disease-modifying RNAi therapeutics that selectively degrade the mutated TTR gene exhibits a great potential to transform the treatment of this disabling affliction.
• The changing status of RNAi-based drugs such as patisiran and inotersen in recent years has paved way to many new approaches in the management of the disease and more focus and funding is being wall mounted to this area. This segment is expected to show strong growth dynamics due to the increase in patient demand for RNA-based treatments for hereditary amyloidosis and the overall growth of knowledge about the disease among health professionals and the population. RNAi therapeutics holds a strategic advantage therefore many pharmaceutical companies embarked on the development of more about advanced RNAi therapeutics and increased the number of RNAi pipelines for this rare but valuable disorder disease treatment.

By Route of Administration, IV infusion segment expected to held the largest share

• IV infusion is anticipated to dominate the mRNA Vaccines and RNAi Therapeutics market in terms of route of administration till 2025. IV infusion has been recommended for RNA based therapies because of its effectiveness in delivering the therapeutic agents right into the blood stream so that they can easily locate the damaged organs/tissues and cells. This route is of considerate significance for RNAi therapeutics and mRNA-based treatments where accuracy and calibrated dosing are critical for the treatment of HHATM, other genetic related diseases, and many other similar diseases. IV infusion is more effective in achieving higher bioavailability because of reduced or no attacks by enzymes that may be occasioned by other access points like oral or subcutaneous.
• Also IV infusions gives the health care givers better control of the treatment because the amount can be regulated at the time of its delivery thus achieving maximum therapeutic benefits. Because IV infusion delivers RNA-based therapies to patient with high clinical accuracy and due to the continued use of IV infusion in offering complex biologics to patients, this segment will keep on dominating the market thereby promoting growth of the market in hospitals and specialized clinics.

mRNA Vaccines and RNAi Therapeutics Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• For the year 2023, North America is expected to lead in this market through innovation, research and development, and through the presence of major pharmaceutical company. This is mainly because the region, particularly driven by the United States, has a highly developed health care system that allows for early approval of new drugs and therapies to receive a wider market share in the world because it was one of the first countries to approve mRNA vaccines against the COVID-19 disease. The market sources estimate that North America accounts for 45% to 50% of the market in 2023. Forced by these influences, favourable policies and research grants from the government have provided additional boost to the market. There are high incidences of emerging and recurrent chronic diseases, an increasing population of elderly, and encouraging pipeline of clinical trial candidates for both BMVCs and RNAi drugs. It is therefore expected that the region’s leadership will persist with further advance characterized by more heretofore unknown advancements in oncology, rare genetic diseases, as well as the fast-growing field of personalized medicine.

Active Key Players in the mRNA Vaccines and RNAi Therapeutics Market

• Alnylam Pharmaceuticals (United States)
• Arcturus Therapeutics (United States)
• Arrowhead Pharmaceuticals (United States)
• BioNTech (Germany)
• CureVac (Germany)
• Dicerna Pharmaceuticals (United States)
• Intellia Therapeutics (United States)
• Ionis Pharmaceuticals (United States)
• Merck & Co. (United States)
• Moderna (United States)
• Pfizer (United States)
• Sanofi (France)
• Silence Therapeutics (United Kingdom)
• Translate Bio (United States)
• Vir Biotechnology (United States)
• Other key Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: mRNA Vaccines and RNAi Therapeutics Market by Disease Type
 4.1 mRNA Vaccines and RNAi Therapeutics Market Snapshot and Growth Engine
 4.2 mRNA Vaccines and RNAi Therapeutics Market Overview
 4.3 Hereditary transthyretin-mediated amyloidosis genetic
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Hereditary transthyretin-mediated amyloidosis genetic: Geographic Segmentation Analysis
 4.4 Acute hepatic porphyria
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Acute hepatic porphyria: Geographic Segmentation Analysis
 4.5 Primary hyperoxaluria Disease Type 1
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Primary hyperoxaluria Disease Type 1: Geographic Segmentation Analysis
 4.6 Atherosclerotic cardiovascular disease
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Atherosclerotic cardiovascular disease: Geographic Segmentation Analysis

Chapter 5: mRNA Vaccines and RNAi Therapeutics Market by Route of Administration
 5.1 mRNA Vaccines and RNAi Therapeutics Market Snapshot and Growth Engine
 5.2 mRNA Vaccines and RNAi Therapeutics Market Overview
 5.3 IV infusion
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 IV infusion: Geographic Segmentation Analysis
 5.4 Subcutaneous
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Subcutaneous: Geographic Segmentation Analysis

Chapter 6: mRNA Vaccines and RNAi Therapeutics Market by End User
 6.1 mRNA Vaccines and RNAi Therapeutics Market Snapshot and Growth Engine
 6.2 mRNA Vaccines and RNAi Therapeutics Market Overview
 6.3 Research Institutes
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Research Institutes: Geographic Segmentation Analysis
 6.4 Hospitals and clinics
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Hospitals and clinics: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 mRNA Vaccines and RNAi Therapeutics Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 ALNYLAM PHARMACEUTICALS
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 ARCTURUS THERAPEUTICS
 7.4 ARROWHEAD PHARMACEUTICALS
 7.5 BIONTECH
 7.6 CUREVAC
 7.7 DICERNA PHARMACEUTICALS
 7.8 INTELLIA THERAPEUTICS
 7.9 IONIS PHARMACEUTICALS
 7.10 MERCK & CO.
 7.11 MODERNA
 7.12 PFIZER
 7.13 SANOFI
 7.14 SILENCE THERAPEUTICS
 7.15 TRANSLATE BIO
 7.16 VIR BIOTECHNOLOGY
 7.17 OTHER KEY PLAYERS

Chapter 8: Global mRNA Vaccines and RNAi Therapeutics Market By Region
 8.1 Overview
 8.2. North America mRNA Vaccines and RNAi Therapeutics Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Disease Type
  8.2.4.1 Hereditary transthyretin-mediated amyloidosis genetic
  8.2.4.2 Acute hepatic porphyria
  8.2.4.3 Primary hyperoxaluria Disease Type 1
  8.2.4.4 Atherosclerotic cardiovascular disease
  8.2.5 Historic and Forecasted Market Size By Route of Administration
  8.2.5.1 IV infusion
  8.2.5.2 Subcutaneous
  8.2.6 Historic and Forecasted Market Size By End User
  8.2.6.1 Research Institutes
  8.2.6.2 Hospitals and clinics
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe mRNA Vaccines and RNAi Therapeutics Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Disease Type
  8.3.4.1 Hereditary transthyretin-mediated amyloidosis genetic
  8.3.4.2 Acute hepatic porphyria
  8.3.4.3 Primary hyperoxaluria Disease Type 1
  8.3.4.4 Atherosclerotic cardiovascular disease
  8.3.5 Historic and Forecasted Market Size By Route of Administration
  8.3.5.1 IV infusion
  8.3.5.2 Subcutaneous
  8.3.6 Historic and Forecasted Market Size By End User
  8.3.6.1 Research Institutes
  8.3.6.2 Hospitals and clinics
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Bulgaria
  8.3.7.2 The Czech Republic
  8.3.7.3 Hungary
  8.3.7.4 Poland
  8.3.7.5 Romania
  8.3.7.6 Rest of Eastern Europe
 8.4. Western Europe mRNA Vaccines and RNAi Therapeutics Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Disease Type
  8.4.4.1 Hereditary transthyretin-mediated amyloidosis genetic
  8.4.4.2 Acute hepatic porphyria
  8.4.4.3 Primary hyperoxaluria Disease Type 1
  8.4.4.4 Atherosclerotic cardiovascular disease
  8.4.5 Historic and Forecasted Market Size By Route of Administration
  8.4.5.1 IV infusion
  8.4.5.2 Subcutaneous
  8.4.6 Historic and Forecasted Market Size By End User
  8.4.6.1 Research Institutes
  8.4.6.2 Hospitals and clinics
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 Netherlands
  8.4.7.5 Italy
  8.4.7.6 Russia
  8.4.7.7 Spain
  8.4.7.8 Rest of Western Europe
 8.5. Asia Pacific mRNA Vaccines and RNAi Therapeutics Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Disease Type
  8.5.4.1 Hereditary transthyretin-mediated amyloidosis genetic
  8.5.4.2 Acute hepatic porphyria
  8.5.4.3 Primary hyperoxaluria Disease Type 1
  8.5.4.4 Atherosclerotic cardiovascular disease
  8.5.5 Historic and Forecasted Market Size By Route of Administration
  8.5.5.1 IV infusion
  8.5.5.2 Subcutaneous
  8.5.6 Historic and Forecasted Market Size By End User
  8.5.6.1 Research Institutes
  8.5.6.2 Hospitals and clinics
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa mRNA Vaccines and RNAi Therapeutics Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Disease Type
  8.6.4.1 Hereditary transthyretin-mediated amyloidosis genetic
  8.6.4.2 Acute hepatic porphyria
  8.6.4.3 Primary hyperoxaluria Disease Type 1
  8.6.4.4 Atherosclerotic cardiovascular disease
  8.6.5 Historic and Forecasted Market Size By Route of Administration
  8.6.5.1 IV infusion
  8.6.5.2 Subcutaneous
  8.6.6 Historic and Forecasted Market Size By End User
  8.6.6.1 Research Institutes
  8.6.6.2 Hospitals and clinics
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkey
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America mRNA Vaccines and RNAi Therapeutics Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Disease Type
  8.7.4.1 Hereditary transthyretin-mediated amyloidosis genetic
  8.7.4.2 Acute hepatic porphyria
  8.7.4.3 Primary hyperoxaluria Disease Type 1
  8.7.4.4 Atherosclerotic cardiovascular disease
  8.7.5 Historic and Forecasted Market Size By Route of Administration
  8.7.5.1 IV infusion
  8.7.5.2 Subcutaneous
  8.7.6 Historic and Forecasted Market Size By End User
  8.7.6.1 Research Institutes
  8.7.6.2 Hospitals and clinics
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research